INTRODUCTION
Fibrin glue is a biologic tissue adhesive found to be an effective sealant and topical hemostatic agent. 1, 2 It consists of concentrated fibrinogen and factor XIII combined with thrombin and calcium to form a coagulum. This preparation stimulates the final stage of clotting cascade, producing a fibrin clot from fibrinogen in the presence of calcium within seconds after administration of the thrombin-activating solution. 3 Some products include antifibrinolytic agents to prevent clot lysis.
Fibrin glue has been used clinically in newborns to achieve hemostasis at cannulation sites in ECMO patients and to seal postoperative thoracic duct leak. 4, 5 Fibrin glue has also been used successfully to treat intractable pneumothorax (PTX) in premature infants, but the literature is limited to single case reports. 6, 7 This report documents the response to therapy and associated complications in a series of eight infants treated with fibrin glue for PTX persisting despite conventional management.
METHODS
Using computerized databases from two tertiary neonatal intensive care units comprising a single teaching program (John Dempsey Hospital and Connecticut Children's Medical Center), patients admitted from 1990 to 2001 with PTX were identified. From this cohort, patients with persistent PTX treated with fibrin glue therapy were identified and a detailed chart review was then performed, focusing on the PTX and its management, treatment with fibrin glue, and post-fibrin glue responses including complications.
Parental verbal or written informed consent was obtained prior to the initiation of fibrin glue therapy. The protocol for the fibrin glue application in each institution was based on the method described by Berger and Gilhooly. 7 A 16-or 18-gauge angiocath was inserted into the pleural air pocket and the chest tube(s) was briefly clamped. The contents of two separate syringes -the first containing thrombin (5000 U) and 10% calcium chloride (5 ml total), and the second containing the source of fibrinogen (either cryoprecipitate or commercially available protein concentrate) with or without an antifibrinolytic agent (aprotinin) (5 ml total) -were injected into the pleural air pocket in rapid succession. The chest tube(s) was unclamped after 3 to 5 minutes.
RESULTS
Eight infants (five boys, three girls) with intractable PTX despite conventional management (chest tube drainage, low lung volume strategy, positioning with the affected side down, and high-frequency oscillation) receiving a total of 10 fibrin glue treatments were identified. These eight patients represent 1.25% (8/636) of all patients with PTX in either NICU during this same time period. Among infants equal to or less than 1500 g (N=2475), 150 (6.1%) developed PTX and seven of these (4.7%) were treated with fibrin glue. The median birth weight was 635 g (range 440-3455 g) and the median gestational age was 24.5 weeks (range 24-39 weeks). Fibrin glue was used when the PTX had persisted for an average of 9.8 days (range 8-16). Seven of the eight infants had respiratory distress syndrome and one had pneumonia as the underlying diagnosis. None of the patients had clinical evidence of pulmonary hypoplasia. Details of each case are shown in Table 1 . Six of the eight infants had a reduction or resolution of the air leak within 24 hours, both clinically and radiographically, with discontinuance of the chest Fibrin glue was used to treat significant pneumothoraces persisting for an average of 10 days in eight newborns. Six of the eight infants had reduction or resolution of persistent air leak within 24 hours of therapy. Two infants received a second course of therapy for recurrences. Complications encountered were bradycardia requiring manual ventilation ( N =2 ), significant hypercalcemia ( N = 2 ), diaphragmatic paralysis ( N = 2), pneumothorax ( PTX ) on the contralateral side ( N = 1 ), and localized tissue necrosis ( N = 1 ). Fibrin glue is an effective treatment for intractable PTX but has significant risks. tube(s) by a mean of 6 days. Two infants had recurrences 1 week later and responded to a second course of fibrin glue therapy. Two infants were critically unstable and died within hours of receiving the fibrin glue; their response to the therapy could not be adequately determined. Of the six responding infants, one died from respiratory failure 3 weeks later, four survived with severe oxygen-dependent BPD, and the one infant with pneumonia recovered without sequelae. None of the three deaths was thought to be directly or indirectly related to fibrin glue treatment.
Complications encountered were bradycardia requiring manual ventilation in two infants and asymptomatic hypercalcemia with total calcium of 17 to 18 mg/dl (normal 9-12 mg/dl) in two, detected within 4 to 6 hours after instillation. There were no EKG changes associated with the hypercalcemia and the levels normalized within 24 hours. One infant developed a contralateral PTX during the fibrin glue application. Two infants developed diaphragmatic paralyses, diagnosed by real-time ultrasound on the ipsilateral side, that were transient, and the infants recovered with conservative medical management. One infant had significant tissue necrosis secondary to the extravasation of calcium-rich fibrin glue into a large communicating subcutaneous bleb. This resolved with conservative therapy.
DISCUSSION
This report demonstrates that fibrin glue is an effective treatment for persistent PTX but has significant associated complications. All patients were unresponsive to standard therapies including chest tube(s) drainage, positioning with the affected side down, low lung volume strategy, and high-frequency oscillation. All patients had frequent episodes of physiologic instability (bradycardia, oxygen desaturation, and hypotension) because of periodic reaccumulation of significant intrapleural air requiring escalation of ventilator settings and/or replacement of existing thoracostomy tube(s). Fibrin glue was administered only after 8 to 16 days of failed standard therapy. There are no guidelines in the literature suggesting the appropriate duration of conservative therapy before considering more invasive procedures, although Bhatia and Matthew 8 suggested that a PTX continuing beyond 7 days in the absence of mechanical problems should be designated as a persistent PTX. In addition to duration of PTX, other factors to consider prior to such invasive therapy(ies) are the size of the bronchopleural fistula, the inspired oxygen concentration and ventilatory settings required, and the clinical stability of the patient.
Previous published experience on the use of fibrin glue for PTX in premature infants has been limited to single case reports. 6, 7 In the two cases previously described, the infants were 26 and 31 weeks' gestation and the fibrin glue was used when the PTX persisted for 3 weeks. One of the infants had a trial of single lung ventilation (not tolerated) before the fibrin glue was used. In the second infant, fibrin glue was used after the PTX reaccumulated on three separate occasions.
An alternative therapy for persistent PTX in neonates is selective intubation of the contralateral bronchus, collapsing the affected lung and facilitating spontaneous healing of ruptured alveoli. This is a technically difficult procedure especially when the left main stem bronchus has to be selectively intubated. Reported complications associated with this therapy include bronchial necrosis or rupture, inability of the infant to tolerate the procedure, and contralateral PTX. 9 The safety and efficacy of selective intubation in combination with high-frequency ventilation are unknown. Other therapies used in adults (pleurectomy, chemical pleurodesis) have not been reported in neonates.
Fibrin glue therapy was associated with significant complications. We speculate that most of the complications (bradycardia, hypercalcemia, and the skin necrosis) are closely linked to the concentration of calcium recommended in the fibrin glue recipe. Whether lower concentrations of calcium might result in an effective sealant with fewer complications is unknown. The two cases of transient diaphragmatic paralyses could have either resulted from the chest tube placement, or directly from the fibrin glue. 10, 11 There is also no literature on the long-term consequences of this method of chemical pleurodesis. In light of these complications, fibrin glue should be reserved for patients with persistent PTX not responding to an adequate trial of conventional therapy.
